James Mullen is the founder of Editas Medicine. He also continues to serve as the Chairman of the company's Board of Directors.
James C. Mullen was appointed Chief Executive Officer of Editas Medicine, a leading genome editing company focused on developing treatments for serious diseases using CRISPR/Cas9 and CRISPR/Cpf1 systems, effective February 15, 2021. He also continues to serve as the Chairman of the company's Board of Directors. Prior to Editas Medicine, Mr. Mullen served as CEO of Patheon N.V. and Biogen, Inc., and holds a B.S. in Chemical Engineering and an M.B.A.
Full founder directory · Investor directory · Company funding database · Fundraising library